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Background: Peritoneal metastasis in gastric cancer represents a ubiquitous human health problem but effective
therapies with limited side effects are still lacking. Although previous research suggested that u-PA was involved
in some tumor metastasis such as lung-specific metastasis, the role of u-PA for peritoneal metastasis in gastric
cancer is still unclear. The aim of this study was to explore whether selective pharmacological blockade of u-PA is
able to affect the peritoneal metastasis of gastric cancer both in vivo and in vitro.
Methods: In the present study, we evaluated the effects and explored the anti-tumor mechanisms of amiloride,
a selective u-PA inhibitor, on a panel of gastric cancer cell lines and in a murine model of human gastric cancer
MKN45.
Results: The study showed that amiloride significantly inhibited the tumor growth and prolonged the survival of
the tumor-bearing mice. In vitro, compared with controls, amiloride could not only significantly down-regulate
the mRNA expression and protein level of u-PA from MKN45 cells with dose dependence but also inhibit the
adhesion of HMrSV5 cells, migration and invasion of MKN45 cells.
Conclusions: The findings in our current report provide evidence that selective u-PA inhibitor amiloride has potent
effects against peritoneal metastasis in gastric cancer, suggesting its possible therapeutic value for the treatment of
gastric cancer.
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Metastasis and recurrence of peritoneal cancer, especially
peritoneal metastasis in gastric cancer, which is often
associated with lymphatic infiltration, is a prevalent cause
of death in patients with gastric cancer in clinical prac-
tice [1-4]. Therapy for peritoneal metastasis in gastric
cancer have been widely studied. Surgical resection is still
the only effective treatment for localized disease; how-
ever, most gastric cancer patients have regional or distant
metastasis at the time of their initial presentation [5].
Effective drugs with limited side effects are still lacking
and the precise mechanisms are not fully understood.
Metastasis is a complex process that mediates detach-
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reproduction in any medium, provided the orsurrounding tissues, spread through the circulation,
extravasion and proliferation in distant organs [6]. The
urokinase (u-PA) is a pivotal proteolytic enzyme known
to regulate the process of metastasis through degrading
extracellular matrix (ECM). In recent years, evidence
increasingly suggests that the level of u-PA secreted by
cancer cells is positively correlated with the capacities
of degrading ECM and invasion [7,8]. However, there is
scarce systematic evidence available to clarify the effects
of the u-PA system in gastric cancer with peritoneal
metastasis.
Moreover, in recent years, amiloride, a selective u-PA
inhibitor, has been proved to have interventional effects
on gastric cancer. Antisense inhibition of u-PA could re-
duce the spread of human ovarian cancer in mice [9]. In
this study, we investigated the effects and explored the
anti-tumor mechanisms of amiloride, a selective u-PA
inhibitor, on a panel of gastric cancer cell lines and in ad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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data might suggest an anti-cancer role of amiloride
against gastric cancer with peritoneal metastasis, and
might set the stage for a new therapy for gastric cancer.
Methods
Reagent and animals
Four to five week-old male BALB/c nude mice under
SPF conditions were obtained from the Experimental
Animal Center (approved by Shanghai East Hospital
Affiliated to Tonggi University ethics committee.) and
given free access to water and food. All experiments
conformed to the animal care and use guidelines of the
Institute’s Animal Care and Use Committee. Amiloride
was obtained from the Sigma Company (Hattiesburg,
USA) and was dissolved in saline.
Cell lines and culture
Human gastric cancer cell lines, MKN45, and human
mesothelial cell line, HMrSV5, were donated by a patient,
Digestive Surgery Institute of Ruijin Hospital, Shanghai
Jiaotong University. Cells were cultured in RPMI 1640 or
Dulbecco’s modified Eagle’s medium (Life Technologies,
Bedford, MA, USA) supplemented with heat-inactivated
fetal bovine serum (FBS) (Gibco, Auckland, New Zealand),
100 units/ml penicillin, and 100 units/ml streptomycin
in a humid chamber at 37°C under 5% CO2. Treated
cells were cultured in fresh medium. The cells in our
study were in logarithmic phase and their living rate
measured by trypan blue was > 90%. Cultures can be
maintained by the addition of fresh medium or replace-
ment of medium. Alternatively, when cells are confluent,
cultures can be established by 1:4 of MKN45 gastric cancer
cells or 1:5 of HMrSV5 mesothelial cells with subsequent
re-suspension.
RNA isolation and RT-PCR
The MKN45 cells were added in the dishes at the
amount of 2 × 106 cells per dish. The incubation times
after cell seeding with amiloride were 6 h, 12 h and 24 h.
After incubation over these time periods, cells were trea-
ted with amiloride at concentrations of 0.01 mM, 0.1 mM
or 1 mM, and RPMI 1640 with 10% FBS was used as a
control. Total RNA was isolated from MKN45 cells using
TRIzol reagent (Qiagen, Japan) according to the manufac-
turer’s instructions. The concentration of RNA was deter-
mined and cDNA was generated using total RNA with
the Reverse Transcriptase kit (Promega, USA). RT-PCR
products were visualized through 2% agarose gels contain-
ing ethidium bromide by electrophoresis. For amplifica-
tion of the desired cDNA, the specific primers were used
as follows: uPA: F:50-AGA ATT CAC CAC CAT CGA
GA-30, R:50-ATC AGC TTC ACA ACA GTC AT-30;GAPDH: F:50-GAA GGTGAAGGTCGGAGT C-30, R:50-
GAA GAT GGT GAT GGG ATT TC-30.
Enzyme-linked immunosorbent assay (ELISA)
Total protein of cell lysates from MKN45 treated by
amiloride were tested for the presence of u-PA. Con-
centration of u-PA was determined with commercial
ELISA kits (Diagnostica international company Temecula,
USA) according to the manufacturer’s instructions. The
reported value is the mean ± SD of duplicate samples.
u-PA activity
In brief, the MKN45 cells treated by amiloride were
collected, washed three times with ice-cold phosphate-
buffered saline (PBS) and lysed in ice-cold lysis buffer
(50 mM Tris–HCl, 150 mM NaCl, 1 mM dithiothreitol
(DTT), 0.5 mM EDTA, 1% nonidet P40 (NP40), 100 μg/ml
PMSF, 1 μg/ml aprotinin, 2 μg/ml leupeptin 100 μM,
sodium vanadate, PH 8.0) for 15 minutes at 1500 g cen-
trifugation. Cellular proteins were extracted from the
MKN45 treated by amiloride. u-PA activity was assessed
with the u-PA Activity Assay Kit (Chemicon International
company, Temecula,USA ) according to the manufacturer’s
instructions. Results are presented as the mean ± SD of
triplicate wells.
Adhesion assays
The adhesion assays we tested in this study followed a
previous description [10]. HMrSV5 cells were plated at a
density of 1 × 104 cells per well in 96-well multiwall
plates 12 to 24 h prior to the assays. Then MKN45 cells
were added in the 96-well multiwall plates at the con-
centration of 1 × 104 cells/ml. The adhesion assay was
determined by the MTT assay [11]. The incubation times,
after cell seeding with amiloride were 6 h, 12 h and 24 h.
After incubation for 6 h, 12 h or 24 h, cells were treated
with amiloride at concentrations of 0.01 mM, 0.1 mM
or 1 mM, and RPMI 1640 with 10% FBS was used as a
control; three wells were included in each concentration.
At every time point the absorbance of 570 nm was mea-
sured with SpectraMax M5 (Molecular Devices), using
wells filled with 200 μl RPMI 1640 with 10% FBS as
blanks. All experiments were performed in triplicate.
The concentration- and time-dependent curves of the
amiloride-treated MKN45 gastric cancer cell lines was
generated as the % cell growth inhibition, using the fol-
lowing formula:
% Inhibition rate = (A570 of control cell - A570 of
treated cells)/A570 of control cells × 100%.
Boyden chamber migration and invasion assays
The assay procedure to measure the in vitro migrating
and invasive capacity of tumor cells was essentially the
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were performed in modified Boyden chambers with 8-μm
pore filter inserts for 24-well plates (BD Bioscience).
Filters were coated with fibronectin (Calbiochem-
Novabiochem). Human mesothelial HMrSV5 cells were
added to the upper chamber at the amount of 2 × 104
in 500 μl of serum-free medium and incubated for 12
to 24 h. For the migration assay, 2×104 MKN45 cells
per 250 μl were seeded on the 20% fibronectin-coated
filters and incubated for 24 h. The lower chamber was
filled with 300 μl of full medium. After incubation for
48 h, the cells were counted by the MTT assay [11].
After incubation for 6 h, 12 h or 24 h, cells were treated
with amiloride in various concentrations (0.01 mM,
0.1 mM or 1 mM), and RPMI 1640 with 10% FBS was
used as a control. Assays were performed in triplicate
or quadruplicate. At every time point the absorbance of
570 nm was measured with SpectraMax M5 (Molecular
Devices). For the invasion assay, 2×104 MKN45 cells at
the concentration of 8×104 cells/ml were seeded on the
10% ice-cold Matrigel (BD Bioscience)-coated filters
and incubated for 24 h. The lower chamber was filled
with 300 μl of full medium. After incubation for 72 h,
the number of penetrated single tumor cells and tumor
cell colonies (collectively called invasion foci) was
counted by the MTT assay [11]. Incubation times after
cell seeding with amiloride were 6 h, 12 h and 24 h. At
these time points, cells were respectively treated with
amiloride at concentrations of 0.01 mM, 0.1 mM or 1 mM,
and RPMI 1640 with 10% FBS was used as a control.
Assays were performed in triplicate or quadruplicate. Every
time point the absorbance at 570 nm was measured with
SpectraMax M5 (Molecular Devices), using wells without
cells as blanks. The invasion of the amiloride-treated
MKN45 gastric cancer cell lines was generated as the %
invasion rate, using the following formula:
Migration rate = A570 of lower/A570 of upper + A570
of lower × 100%.
In vivo evaluation
The tumor model used in this study has been described
previously [15]. Briefly, 5 × 106 MKN45 cells were intra-
peritoneally injected into 4- to 5-week-old male BALB/c
nude mice. The mice were randomly divided into two
groups of 12 mice. Fourteen days after MKN45 implant-
ation, the treatment groups received their first dose of
amiloride dissolved in a saline solution. Amiloride dos-
age and administration schedules were based on our
preliminary toxicologic and pharmacokinetic studies.
Briefly, amiloride was given via oral administration to
tumor-bearing mice at 50 mg/kg every day at the first
three days of one week for a total time of four weeks. In
parallel, the control group received the saline solution.General clinical observations of the mice, including de-
termination of body weight and tumor growth (data not
shown), were made twice weekly. The mice were sacri-
ficed when they became moribund, and the sacrifice date
was recorded to calculate the survival time.
Statistical analysis
Statistical analysis was performed with the SPSS soft-
ware system (SPSS for Windows, version 13.0; SPSS Inc,
Chicago, IL). Parametric data were statistically analyzed
by the Student’s t-test or one way analysis of variance
(ANOVA) followed by post hoc tests when appropriate.
Differences in non-parametric data were evaluated by
the Mann–Whitney U-test. Survival curves were statis-
tically analyzed using Kaplan-Meier test. Data were
expressed as means ± SD. A significant difference was
defined as P < 0.05.
Results and discussion
Reduction of u-PA protein and activity of u-PA by
amiloride
u-PA, which by its signaling is essential for the onset of
gastric cancer, plays an important role in both the
human and animal model of gastric cancer [16-18]. As
shown in Figure 1A, the amiloride challenge led to re-
duction of the expressions of mRNA of u-PA after 24 h
with dosage (0.01 mM to 1 mM) dependence, compared
with control group (Figure 1A). The ELISA method was
used to detect u-PA protein content in the cell lysates of
MKN45 cells after treatment with different concentra-
tions of amiloride. At the time point of 6 h, production
of u-PA was significantly lower in the amiloride-treated
group than in the control. Compared with the level of
u-PA in the control (0.07 ng/ml), u-PA in the group
treated with 0.1 mM to 1 mM amiloride was 0.068, 0.03
and 0.02 respectively (Figure 1B,C). However, at 12 h
and 24 h, we found no significant difference between the
control and amiloride group in the expression of u-PA
protein. We also observed that higher dosage of
amiloride could inhibit the activity of u-PA in the
MHK45 gastric cancer cell line (Figure 1).
Amiloride interfered with adhesion of mesothelial
cell line HMrSV5
In vitro, compared with controls, amiloride significantly
decreased the adhesion of mesothelial HMrSV5 cells. This
inhibition was time- and dose-dependent (Figure 2A).
Mediation of Boyden chamber migration and invasion
of MKN45 gastric cancer cells in vitro by amiloride
We investigated the effects of amiloride on the Boyden
chamber migration of MKN45 gastric cancer cells. As
shown (Figure 2), amiloride slightly suppressed Boyden
chamber migration of MKN45 cells. Compared with the
Figure 1 Amiloride down-regulated the production of urokinase (u-PA) in MKN45 gastric cancer cells. The MKN45 cells were added in the
dishes at the amount of 2 × 106 cells per dish. After incubation for 6 h, 12 h or 24 h, cells were treated with amiloride in concentrations of 0.01
mM, 0.1 mM or 1 mM, and RPMI 1640 with 10% FBS was used as a control. (A) Expression of u-PA mRNA. (B) The level of u-PA. (C) u-PA activity.
Con, control. Data are means ± SD, *P < 0.05 vs. Con.
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tion rates with 0.01 mM to 1 mM amiloride were
57.51%, 56.14% and 55.44%, respectively. We also found
that in comparison to the invasion rate of the control
group (38.04%), 0.01 mM and 0.1 mM amiloride reduced
the invasion rate to 22.08% and 33.97% respectively.
However, the invasion rate of 1 mM amiloride was
57.33% (Figure 2B). These results suggest that amiloride
might mediate the migration and invasion of MKN45
cells (Figure 2).Figure 2 Adhesion assay and Boyden chamber migration/invasion as
mesothelial cell line HMrSV5 tested by MTT (%). (B) Boyden chamber migra
Data are means ± SD, *P < 0.05 vs. Con.Amiloride down-regulated the mRNA expression of u-PA
We analyzed the effects of amiloride on the mRNA
expression of uPA in the gastric cancer cell line
MKN45 (Figure 3). As shown, the amiloride challenge
led to time- and dosage-dependent reduction of the
expressions of mRNA of the u-PA from 12 h to 24 h
and at 0.01 mM to 1 mM, compared with he control
group (Figure 3). These results indicate that amiloride
suppressed production of u-PA in MKN45 gastric can-
cer cells.say of amiloride treatment. (A) Adhesion assay of amiloride-treated
tion and invasion assay of amiloride tested by MTT (%). Con, control.
Figure 3 Amiloride down-regulated the mRNA expression of urokinase (u-PA) in MKN45 gastric cancer cells. The MKN45 cells were
added at the amount of 2 × 106 cells per dish. After incubation for 6 h, 12 h or 24 h, cells were treated with amiloride in concentrations of
0.01 mM , 0.1 mM or 1 mM, and RPMI 1640 with 10% FBS was used as a control. Total RNA was isolated from MKN45 cells using TRIzol reagent
(Qiagen, Japan) according to the manufacturer’s instructions. The concentration of RNA was determined and cDNA was generated using total
RNA with the Reverse Transcriptase kit (Promega, USA). (A) RT-PCR analysis for u-PA in MKN45 gastric cancer cells. Con, control. Data are
means ± SD, *P < 0.02 vs. Con.
Figure 4 Amiloride inhibited MKN45 derived-tumor growth. We
intraperitoneally injected 5 × 106 MKN45 cells into 4- to 5-week-old
male BALB/c nude mice. The mice were randomly divided into two
groups of twelve per group; 14 days after MKN45 implantation, the
treatment group received the first dose of amiloride dissolved in
saline solution. Dosage and administration schedules were based on
our preliminary toxicologic and pharmacokinetic studies; amiloride
was given orally to tumor-bearing mice at 50 mg/kg every day at
the first three days of one week for a total time of four weeks. In
parallel, the control group received saline solution. Mice were
sacrificed when they became moribund, and the sacrifice date was
recorded to calculate the survival time. (A) Amiloride inhibited
MKN45-derived tumor growth. Con, control; Amiloride, group
treated with 50 mg/kg amiloride.
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prolonged the survival of the tumor-bearing mice
Having shown that amiloride suppressed tumor cell
growth, we investigated its antitumor effects in a murine
model of gastric cancer. As shown in Figure 4, at the
end of the experiment, the oral administration of amilor-
ide at 50 mg/kg led to respective reductions in tumor
growth, compared with that in control mice treated with
saline solution. We measured the animal weight and
found the weight of mice in the amiloride-treated group
was decreased. We also observed appetite, fur, behavior,
etcetera, to evaluate the physical status, and there were
no changes in gross measures. Most intriguing, as shown
in Figure 5, at the end of the study, compared with the
control, the 50 mg/kg amiloride group had a 70-day sur-
vival median of 51 days. Although the 50 mg/kg group
had a similar 70-day survival rate to the control, the
death date was obviously delayed. These data suggest
that oral administration of amiloride had effects on inhi-
biting MKN45-derived tumor growth and prolonging
the survival of the tumor-bearing mice.
Discussion
Treatment of human peritoneal metastasis in gastric
cancer remains a major clinical problem [19]. Metastasis
is associated with the process of cancer cells from a pri-
mary site invading surrounding tissues [20,21]. Here, we
clearly show that blockade of the u-PA with amiloride
suppresses the development of peritoneal metastasis in
gastric cancer.
Figure 5 Survival function of MKN45 gastric tumor-bearing
mice treated with amiloride. Briefly, 5 × 106 MKN45 cells were
intraperitoneally injected into 4- to 5-week-old male BALB/c nude
mice. The mice were randomly divided into two groups of six per
group; 15 days after MKN45 implantation, the treatment group
received the first dose of amiloride dissolved in a saline solution.
Amiloride was given orally to tumor-bearing mice at 50 mg/kg every
day at the first three days of one week for a total time of two
weeks. In parallel, the control group received saline solution. Mice
were sacrificed when they became moribund, and the sacrifice date
was recorded to calculate the survival time. The red line represents
control and the green line represents the amiloride group. P< 0.05.
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transport, competitively inhibits the catalytic activity of
u-PA, without decreasing those of t-PA, or plasmin [22].
Thus, amiloride may be a useful model compound for
the development of u-PA-specific protease inhibitors [23].
u-PA is a pivotal proteolytic kinase known to regulate the
process of cancer metastasis [24] . Lokman et al. have
observed that u-PA knockdown could inhibit the pro-
liferation of cancer cells in peritoneal metastasis [25].
Jankun et al. reported that treatment of amiloride could
not only reduce the size of prostate cancer xenografts
in severe combined immunodeficient mice, but also
help survival [26]. To further study the inhibition
effects of u-PA on gastric cancer peritoneal metastasis,
we investigated the effects and explored the anti-tumor
mechanisms of amiloride, a selective u-PA inhibitor, on
a panel of gastric cancer cell lines and in a mouse
model of human gastric cancer MKN45. Previous re-
search found that amiloride participated in the transcrip-
tional and post-transcriptional regulation of u-PA gene
expression in colon cancer cells [27]. Ogura et al. also
agreed that amiloride played a specific role in inhibiting
u-PA activity [28]. We analyzed the effects of amiloride
on mRNA and protein production and activity of u-PA in
MKN45 gastric cancer cells in vitro. In accordance toprevious reports, the results showed that amiloride not
only decreased both mRNA and protein production of
u-PA in MKN45 gastric cancer cells, but also reduced
the u-PA activity of MKN45 cell line. Amiloride inhib-
ited MKN45-derived tumor growth and prolonged the
survival of the tumor-bearing mice. Consequently, it
might be concluded that the inhibition of u-PA by
amiloride could suppress peritoneal metastasis in gastric
cancer. Furthermore, activation of Na+/H+ exchange
activity is found as a ubiquitous response to early growth
factors, such as u-PA [29]. uPA/uPAR-mediated tumor
progression and metastasis requires Na+/H+ exchange
[30]. Amiloride is reported as a Na+/H+ exchange inhibi-
tor to inhibit cancer cell invasion and motility [31-33].
Taken together, it is believable that amiloride may first
inhibit u-PA expression and then affect Na+/H+ ex-
change activity, ultimately resulting in suppression of
peritoneal metastasis in gastric cancer.
In a recent study on breast cancer cells in vitro, Tuck
et al. had found that the same as anti-u-PA antibody
and anti-u-PAR antibody, amiloride significantly inhib-
ited migration and invasion of breast cancer cells [34].
Evans et al. observed that oral amiloride inhibited lung
metastasis in pulmonary metastasis in the rat mammary
cancer model and this effect was positively correlated
with time- and dose-dependence [35]. In SCID mice sub-
cutaneously injected with prostate cancer cells, JanKun
et al. found that oral amiloride could potently inhibit
tumor growth and prolong the survival of tumor bearing
mice [26]. Evans et al. reported that amiloride could
dose- and time-dependently inhibit cancer cell metastasis
[36]. In the adhesion test between MKN45 cells and
mesothelial cells, we found the inhibition of adhesion by
amiloride was correlated with inhibition of the growth
of MKN45 cells. In addition, at the time point of 24 h,
0.01 mM amiloride had lost the inhibitive role of adhe-
sion, which might be related to the inhibition of u-PA
activity caused by long-time stimulation of amiloride at
a low concentration.Conclusions
In our study, compared with controls, the selective u-PA
inhibitor amiloride significantly decreased the adhesion
of mesothelial HMrSV5 cells, and inhibited the adhesion
of the gastric cancer cell MKN45 in vitro. However,
there was no significant effect of amiloride on migration
of gastric cancer cell MKN45 peritoneal metastasis. It is
interesting to further elucidate the precise mechanism of
cancer cell migration and invasion in gastric cancer peri-
toneal metastasis mediated by u-PA inhibition.Competing interests
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